Clinical trial
A Phase 3, Multi-Center, Randomized Study to Assess The Efficacy, Safety and Tolerability of Subretinal OCU400 Gene Therapy for the Treatment of Retinitis Pigmentosa
NCT06388200 is registered in ClinicalTrials.gov with Ocugen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multi-Center, Randomized Study to Assess The Efficacy, Safety and Tolerability of Subretinal OCU400 Gene Therapy for the Treatment of Retinitis Pigmentosa
- Lead sponsor
- Ocugen
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 18, 2024
- Completion date
- February 12, 2027
- Enrollment
- 140 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.